Rare disease patients win access to 'overpriced drugs'

English Español Français العربية Русский

RSS

Radio TV

LANGUAGE
English Español Français العربية Русский Documentary CCTV+

Radio TV

Download

01:17

Last year, the targeted drug for the rare disease spinal muscular atrophy (SMA) was turned from a price of 700,000 RMB (around $100,000) to an affordable national healthcare insured drug after the National Healthcare Security Administration's 2021 insured drug Medicare negotiations.

Starting January 1, 2022, SMA patients across the country were getting access to these "overpriced drugs".